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Introduction {#sec1}
============

Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), can self-renew or potentially differentiate into all cell types, a phenomenon known as pluripotency ([@bib13]; [@bib55]). PSCs hold great promise for basic biomedical research, the production of genetically modified animals, and future clinical applications. Distinct pluripotent states, termed naive and primed pluripotency, have been described ([@bib43]). Naive PSCs resemble the preimplantation embryo inner cell mass ([@bib4]) while primed PSCs resemble postimplantation embryonic epiblasts ([@bib57]). These states are reversible and interconvertible. The pluripotency of PSCs is known to determine the fate of embryonic development, and high-quality PSCs can produce chimeras with high efficiency when they are introduced into a blastocyst ([@bib25]) and can develop into viable offspring by tetraploid complementation ([@bib69]; [@bib70]). Understanding the molecular mechanisms that influence pluripotency acquisition and maintenance is key to advancing therapeutic applications of PSCs.

Cells produce ATP by exploiting glycolysis and oxidative phosphorylation (OXPHOS) in different proportions to obtain energy for survival. Somatic cell reprogramming resets cellular metabolism to a state of relatively high glycolysis and low OXPHOS ([@bib15]). PSCs in a naive state are highly oxidative compared with primed cells. The progression from naive to primed pluripotency is characterized by a metabolic shift from OXPHOS to glycolysis ([@bib72]), and resetting primed pluripotent cells to a naive state necessitates a reversal of the metabolic switch ([@bib5]; [@bib56]). Mitochondria are essential organelles in all nucleated cells that function mainly to generate cellular ATP by OXPHOS via the electron transport chain (ETC, complexes I--IV) and ATP synthase (complex V). Primed PSCs maintain lower mitochondrial function than naive cells ([@bib65]). In addition, the mitochondrial membrane potential ([@bib54]), ATP ([@bib67]), reactive oxygen species (ROS) ([@bib50]; [@bib71]), and mitochondrial dynamics ([@bib28]; [@bib70]) were reported as the key factors responsible for cell-fate changes. However, the factors that determine mitochondrial function in PSCs and their regulatory mechanism remain unclear.

Genetic lesions of either endogenous or exogenous origin are major threats to the function of PSCs ([@bib61]; [@bib63]). PSCs rely on a very robust DNA damage response (DDR) to detect and control specific types of DNA damage. Once DNA damage is unresolvable, PSCs avoid the propagation of genetic lesions by undergoing regulated cell death ([@bib10]; [@bib37]) or losing pluripotency ([@bib32]; [@bib34]). Among all types of DNA lesions, DNA double-strand breaks (DSBs) are arguably the most dangerous ([@bib26]), and PSCs predominantly use homologous recombination (HR) to repair DSBs ([@bib59]). Failure of HR repair systems typically leads to severe consequences, such as genomic instability in cellular reprogramming ([@bib17]; [@bib31]). Thus, efficacious DSB repair is a key element in the maintenance of high genomic integrity. However, the mechanisms that protect genomic integrity and the key regulators involved are not completely clear.

In this study, we identified methylenetetrahydrofolate dehydrogenase (NAD^+^-dependent), methenyltetrahydrofolate cyclohydrolase (*Mthfd2*) as an important regulator of pluripotency in mouse PSCs. *Mthfd2* is a bifunctional enzyme with methylene dehydrogenase and cyclohydrolase activity involved in mitochondrial folate one-carbon metabolism ([@bib58]). *Mthfd2* plays an essential role in mouse embryonic development, because inactivation of this gene in mice was demonstrated to be lethal ([@bib11]). *MTHFD2* is markedly elevated in many cancers and positively correlated with poor prognosis in patients with cancer ([@bib33]; [@bib36]; [@bib47]). In addition, *MTHFD2* is localized to the nucleus and affects proliferation independent of its enzymatic activity in cancer cells ([@bib19]). However, the function of *Mthfd2* in PSCs has not been reported. Here, we demonstrated that *Mthfd2* mediates both mitochondrial function and DNA repair to determine the pluripotency state of PSCs, ultimately improving their potential use in various applications and their safety.

Results {#sec2}
=======

A Microarray Assay Identifies Putative New Pluripotency-Regulating Genes in iPSCs {#sec2.1}
---------------------------------------------------------------------------------

We reanalyzed the microarray data from iPSCs of different quality initially generated in our laboratory and demonstrated the quality of the iPSCs based on their *in vitro* developmental potential ([@bib20]; [@bib23]). High-quality iPSCs underwent germline transmission or produced mice derived completely from iPSCs by tetraploid complementation, while low-quality iPSCs produced only chimeras with a low coat color contribution. Candidate genes were selected based on their higher expression in high-quality iPSCs than in low-quality iPSCs ([Table S1](#mmc2){ref-type="supplementary-material"}). Among these candidates, *Esrrb*, *Sall4*, *Gadd45a*, and *Rab32* were previously reported to be important for enhancing iPSC generation and modulating ESC pluripotency ([@bib6]; [@bib14]; [@bib46]; [@bib66]). Besides, some new potential regulators such as *Mthfd2* were identified ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

*Mthfd2* Plays a Key Role in Mouse ESCs to Maintain Self-Renewal {#sec2.2}
----------------------------------------------------------------

To validate the role of the candidate genes in regulating mouse ESC (mESC) self-renewal, we separately used short hairpin RNAs (shRNAs) to suppress the expression of candidate genes in E14 mESCs. *Mthfd2* knockdown (KD) resulted in loss of typical stem cell morphology ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D), with reduced alkaline phosphatase (AP) staining ([Figure 1](#fig1){ref-type="fig"}A). The expression of pluripotency marker genes was downregulated and that of lineage marker genes upregulated ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#mmc1){ref-type="supplementary-material"}E), showing that *Mthfd2* depletion results in differentiation of mESCs. We then knocked down *Mthfd2* in another G4 mESC line and found that the results were consistent with those in *Mthfd2* KD E14 mESCs ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Additionally, homozygous *Mthfd2* knockout (KO) mESCs were characterized by the loss of typical mESC morphology, abnormal expression of marker genes, and compromised cell proliferation ([Figures 1](#fig1){ref-type="fig"}D--1G and S1H). Forced expression of *Mthfd2* rescued the *Mthfd2* KO-induced differentiation and compromised cell proliferation ([Figures 1](#fig1){ref-type="fig"}H--1K). In addition, MTHFD2 protein expression was gradually silenced during the differentiation of mESCs into embryoid bodies (EBs) ([Figure 1](#fig1){ref-type="fig"}L). These results demonstrate a key role of *Mthfd2* in the maintenance of mESC self-renewal.Figure 1*Mthfd2* Is Important for mESCs to Maintain Self-Renewal(A) Representative results of *Mthfd2* KD mESCs with AP staining. Scale bars, 100 μm.(B and C) qRT-PCR analysis of mRNA levels of pluripotency marker genes (B) and lineage marker genes (C) in *Mthfd2* KD mESCs.(D) Representative results of *Mthfd2* KO mESCs with AP staining. Scale bars, 200 μm.(E and F) qRT-PCR analysis of mRNA levels of pluripotency marker genes (E) and lineage marker genes (F) in *Mthfd2* KO mESCs.(G) Representative growth curve of *Mthfd2* KO mESCs.(H) Representative results of overexpressed (OE) *Mthfd2*-*Mthfd2* KO mESCs with AP staining. Scale bar, 200 μm.(I and J) qRT-PCR analysis of mRNA levels of *Mthfd2* (I) and pluripotency marker genes (J) in OE *Mthfd2*-*Mthfd2* KO mESCs.(K) Representative growth curve of OE *Mthfd2*-*Mthfd2* KO mESCs.(L) Western blot analysis of the levels of the MTHFD2 protein during differentiation of mESCs. GAPDH was used as a loading control.Data in (B), (C), (E), (F), (I) and (J) are pooled from three independent experiments (mean ± SD) relative to EF1-α and the control mESCs. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

*Mthfd2* Facilitates Mouse iPSC Induction {#sec2.3}
-----------------------------------------

We used *Oct4*, *Sox2*, and *Klf4* (OSK) combined with various candidate factors, including *Mthfd2*, in a subsequent reprogramming assay ([@bib55]). Mouse embryonic fibroblasts (MEFs) expressing a green fluorescent protein (GFP) reporter driven by an *Oct4* promoter and enhancer (termed OG2 MEFs) were used for iPSC induction. To ensure the reliability of our results, we tested two culture conditions, serum + LIF (leukemia inhibitory factor) mESC medium and KOSR medium, the latter of which has been reported to enhance iPSC induction ([@bib38]). The number of Oct4-GFP^+^ colonies generated by coinfection of *Mthfd2* and OSK was increased approximately 2-fold relative to that in control cells which coinfection of empty vector and OSK (p \< 0.05) in both mESC medium ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B) and KOSR medium ([Figures 2](#fig2){ref-type="fig"}A and 2B). We used doxycycline-inducible MEFs expressing *Oct4*, *Sox2*, *Klf4*, and *c-Myc* (OSKC) reprogramming factor TF4 ([@bib16]) for reprogramming to further confirm the *Mthfd2*-mediated improvements. The number of AP^+^ colonies was increased in the *Mthfd2*-overexpressing group compared with that in the control group ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D) (p \< 0.05). These results indicated that *Mthfd2* facilitates the induction of iPSCs.Figure 2*Mthfd2* Promotes Complete Reprogramming of iPSCs(A) The reprogramming efficiencies in KOSR medium. OSK + control (Ctr) cells were used as a control. Data are pooled from three independent experiments (mean ± SD). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control.(B) Full-well mosaic images of Oct4-GFP^+^ cells and AP^+^ colonies are shown for OSK+Ctr and OSKM2 iPSCs in KOSR medium.(C) Immunofluorescence (IF) staining for pluripotency marker proteins in OSKM2 iPSCs. DAPI was used to indicate the nuclei. Scale bars, 100 μm.(D) IF staining for GATA6 (endoderm), NESTIN (ectoderm), and α-smooth muscle actin (mesoderm) in EBs derived from OSKM2 iPSCs. DAPI was used to indicate the nuclei. Scale bars, 100 μm.(E) H&E staining of teratomas derived from OSKM2 iPSCs. Scale bars, 100 μm.(F) Representative images of chimeric mice (F1) and their offspring (F2).(G) Live-born pups obtained from OSKM2 iPSCs were tested by tetraploid complementation.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

*Mthfd2* Improves the Quality of iPSCs {#sec2.4}
--------------------------------------

All iPSCs induced with *Mthfd2* (OSKM2 iPSCs) showed typical mESC-like morphology and expressed Oct4-driven GFP ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Exogenous retroviral expression of OSK and *Mthfd2* was silenced ([Figure S2](#mmc1){ref-type="supplementary-material"}F), and the expression of pluripotency marker genes was similar in OSKM2 iPSCs and mESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}G). In addition, two master transcription factors (*Nanog* and *Sox2*) and the mESC-specific surface marker SSEA1 were expressed in OSKM2 iPSCs ([Figure 2](#fig2){ref-type="fig"}C).

We conducted EB and teratoma formation assays to assess the ability of OSKM2 iPSCs to differentiate *in vitro* and *in vivo*. The EBs and teratomas derived from OSKM2 iPSCs differentiated into cells of all three germ layers ([Figures 2](#fig2){ref-type="fig"}D and 2E). Furthermore, the developmental potential of OSKM2 iPSCs *in vivo* was tested via 8-cell embryo injection ([@bib62]), and chimeric mice derived almost completely from iPSCs were produced and had the ability of germline transmission ([Figure 2](#fig2){ref-type="fig"}F). Next, we tested the developmental potential of OSKM2 iPSCs *in vivo* by tetraploid complementation ([@bib69]). Remarkably, OSKM2 iPSCs gave rise to viable all-iPSC-derived pups ([Figure 2](#fig2){ref-type="fig"}G) with higher efficiency than control OSKC iPSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Collectively, these results indicated that *Mthfd2* improves the quality of iPSCs.

*Mthfd2* Depletion Shifts Glucose Metabolism from OXPHOS to Glycolysis in mESCs {#sec2.5}
-------------------------------------------------------------------------------

MTHFD2 was reported to be an important enzyme in mitochondrial one-carbon metabolism ([@bib58]). Two MTHFD2-specific inhibitors, MIN and NIT ([@bib2]), were used to inhibit MTHFD2 enzymatic activity in mESCs. Both MIN- and MIT-treated mESCs (MI-mESCs) maintained typical stem cell morphology and pluripotency-associated marker gene expression ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). Therefore, we speculated that the MTHFD2 has non-enzymatic functions in mESCs. To characterize the global function of *Mthfd2* in mESCs, we analyzed changes in the transcriptome due to suppression of *Mthfd2* ([Figure S3](#mmc1){ref-type="supplementary-material"}D and [Table S2](#mmc3){ref-type="supplementary-material"}). Among the differentially expressed genes (DEGs), pluripotency-associated genes were downregulated in *Mthfd2* KD mESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Interestingly, gene ontology (GO) terms such as glycolytic process were among the top ten terms enriched in upregulated genes ([Figure S3](#mmc1){ref-type="supplementary-material"}F), and additional GO terms associated with carbohydrate metabolism were among the terms enriched in upregulated genes (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}A). Glucose metabolism is a complex and dynamic process and is the most potent modulator of PSC pluripotency states and cell-fate changes ([@bib5]; [@bib52]; [@bib72]). Subsequently, we evaluated whether the cellular glucose metabolism state was altered in *Mthfd2* KD mESCs. Among the DEGs, the levels of key glycolytic genes were increased and those of some key OXPHOS genes were decreased in *Mthfd2* KD mESCs ([Figures 3](#fig3){ref-type="fig"}B and 3C). Lower intracellular glucose levels and higher intracellular lactate levels were detected in *Mthfd2* KD cells than in control cells ([Figures 3](#fig3){ref-type="fig"}D and 3E), indicating increased consumption of glucose and production of lactate in *Mthfd2* KD mESCs. Therefore, *Mthfd2* depletion shifts glucose metabolism from OXPHOS to glycolysis in mESCs.Figure 3MTHFD2 Interacts with Complex III to Regulate Glucose Metabolism in mESCs(A) Summary of enriched GO terms that were potently upregulated and downregulated by *Mthfd2*. p \< 0.05. For details, see [Table S2](#mmc3){ref-type="supplementary-material"}.(B and C) Heatmap of DEGs about glycolysis (B) and OXPHOS (C) between control mESCs and *Mthfd2* KD mESCs.(D and E) Examination of intracellular glucose levels (D) and lactate levels (E) in *Mthfd2* KD mESCs. Data are pooled from three independent experiments (mean ± SD). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control.(F and G) CoIP results showing the specific interactions between endogenous MTHFD2 and both UQCRC2 and CYC1 in mESCs (F) and in the cytoplasm fraction of mESCs (G).(H and I) GST pull-down assays for interaction between UQCRC2-His (H), CYC1-His (I), and MTHFD2-GST fusion proteins at 250 mM NaCl containing GST binding buffer.(J) Western blot analysis of the levels of the UQCRC2 and CYC1 proteins in *Mthfd2* KD mESCs. β-Tubulin was used as a loading control.(K) Western blot analysis of the levels of UQCRC2 protein in *Mthfd2* KD mESCs at indicated times post cycloheximide (CHX) treatment. GAPDH was used as a loading control.See also [Figures S3--S5](#mmc1){ref-type="supplementary-material"}.

MTHFD2 Interacts with Mitochondrial ETC Complex III in Mitochondria {#sec2.6}
-------------------------------------------------------------------

To understand the mechanism by which *Mthfd2* functions in mESCs, we used an immunoprecipitation and mass spectrometry (IP-MS) assay to search for proteins that interact with MTHFD2. MTHFD2 was localized to both the nucleus and mitochondria in mESCs ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), and its function in mESCs, particularly in the nucleus, remains unknown. Hence, we separated nuclear and cytoplasmic fractions from Mthfd2-FLAG mESCs and subjected them to IP-MS ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4F).

Among the identified MTHFD2 partners were the complex III members UQCRC2 and CYC1 ([Figure S4](#mmc1){ref-type="supplementary-material"}G and [Table S3](#mmc4){ref-type="supplementary-material"}). Complex III is a component of the mitochondrial ETC, via which OXPHOS is mediated to generate ATP in eukaryotic cells ([@bib21]; [@bib40]). Given the upregulation of glycolysis in *Mthfd2* KD mESCs, the interaction between MTHFD2 and complex III was particularly interesting. First, the interaction between FLAG-tagged MTHFD2 and hemagglutinin (HA)-tagged UQCRC2 was verified in E14 mESCs by reciprocal coimmunoprecipitation (coIP) experiments ([Figure S5](#mmc1){ref-type="supplementary-material"}A). The specific interactions between endogenously expressed MTHFD2 and both UQCRC2 and CYC1 were then verified in E14 mESCs ([Figure 3](#fig3){ref-type="fig"}F). We further verified that MTHFD2 formed protein complexes with UQCRC2 and CYC1 in the cytoplasmic fraction ([Figure 3](#fig3){ref-type="fig"}G). To address the questions of whether the interactions between MTHFD2 and those proteins were direct, we conducted glutathione S-transferase (GST) pull-down assays using recombinant proteins. No direct interaction between MTHFD2-GST and either UQCRC2-His or CYC1-His was detected ([Figures 3](#fig3){ref-type="fig"}H and 3I). Thus, these results provide evidence for an indirect interaction between MTHFD2 and complex III in mitochondria of mESCs.

The protein level of UQCRC2 were reduced in *Mthfd2* KD mESCs compared with control mESCs (Figure S5B) but did not differ between MI-mESCs and control mESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Treatment with a 26S proteasome inhibitor, MG132, efficiently prevented the *Mthfd2* depletion-induced reduction in UQCRC2 expression ([Figure 3](#fig3){ref-type="fig"}J). By treating cells with the protein synthesis inhibitor cycloheximide, we found that the half-life of UQCRC2 was considerably shortened upon depletion of *Mthfd2* ([Figure 3](#fig3){ref-type="fig"}K). Thus, *Mthfd2* might play a role in maintaining the stability of the UQCRC2 protein.

*Mthfd2* Deficiency Induces Mitochondrial Dysfunction by Regulating the Activity of Complex III {#sec2.7}
-----------------------------------------------------------------------------------------------

The main function of complex III is to transfer electrons between ubiquinol and cytochrome *c*, thus generating an electrochemical potential that drives ATP synthesis ([@bib8]). In addition, complex III is the major site of ROS generation ([@bib7]). The mitochondrial membrane potential (MMP) and ATP production were decreased ([Figures 4](#fig4){ref-type="fig"}A and 4B) and cellular ROS levels were increased in *Mthfd2* KD mESCs ([Figure 4](#fig4){ref-type="fig"}C). These effects are consistent with those observed in cells treated with antimycin A (a complex III inhibitor), which impairs mitochondrial function ([Figures 4](#fig4){ref-type="fig"}D and 4E), and indicated that *Mthfd2* deficiency induces mitochondrial dysfunction in mESCs.Figure 4*Mthfd2* Deficiency Induces Mitochondrial Dysfunction by Reducing *Uqcrc2* Expression(A) Measurements of the mitochondrial membrane potential (MMP) in *Mthfd2* KD mESCs using tetramethylrhodamine methyl ester (TMRE).(B) Total ATP levels in *Mthfd2* KD mESCs.(C) Flow-cytometry analysis of ROS levels in *Mthfd2* KD mESCs.(D) Measurements of the MMP in antimycin A-treated mESCs (AA-mESCs) using TMRE.(E) Flow-cytometry analysis of ROS levels in AA-mESCs.(F) Measurements of the MMP in *Uqcrc2* KD mESCs using TMRE.(G) Flow-cytometry analysis of superoxide levels in *Uqcrc2* KD mESCs.(H) Total ATP levels in *Uqcrc2* KD mESCs.(I and J) Examination of intracellular glucose levels (I) and lactate levels (J) in *Uqcrc2* KD mESCs.(K) Measurements of the MMP in OE *Uqcrc2*-*Mthfd2* KD mESCs using TMRE.(L) Flow-cytometry analysis of ROS levels in OE *Uqcrc2*-*Mthfd2* KD mESCs.All data are pooled from three independent experiments (mean ± SD). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control. A representative histogram (left) and quantification of the mean fluorescence intensity (right) are presented for (A), (C) to (G), (K), and (L). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The mitochondrial dysfunction induced by *Mthfd2* depletion resembled the phenotype observed in cells with *Uqcrc2* deficiency, which leads to complex III deficiency ([@bib1]; [@bib41]). *Uqcrc2* KD cells exhibited reduced MMP and ATP production, increased levels of superoxide (a major ROS generated in mitochondria), and a shift of glucose metabolism to glycolysis ([Figures 4](#fig4){ref-type="fig"}F--4J). Moreover, forced expression of *Uqcrc2* effectively rescued the *Mthfd2* KD-induced changes in the MMP ([Figure 4](#fig4){ref-type="fig"}K) and the cellular ROS level ([Figure 4](#fig4){ref-type="fig"}L). In addition, the cellular ROS level ([Figure S5](#mmc1){ref-type="supplementary-material"}D) and the MMP ([Figure S5](#mmc1){ref-type="supplementary-material"}E) did not differ between MI-mESCs and control mESCs. Therefore, *Mthfd2* depletion induces mitochondrial dysfunction through inhibition of complex III activity caused by a decrease in UQCRC2 expression.

*Mthfd2* Depletion Hinders DNA Repair in mESCs {#sec2.8}
----------------------------------------------

In addition to GO terms related to glycolysis, GO terms such as DNA repair were among the top ten terms enriched in downregulated genes ([Figure S6](#mmc1){ref-type="supplementary-material"}A), and additional terms such as double-strand break repair via HR were enriched in downregulated genes (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}A). PSCs rely on a very robust DNA repair response to control DNA damage, and if DNA damage is unresolvable, PSCs prevent the propagation of genetic lesions by undergoing regulated cell death ([@bib37]) or losing pluripotency ([@bib32]; [@bib34]). Therefore, we examined whether *Mthfd2* deficiency altered DNA damage levels in mESCs. Among the DEGs, DNA repair-associated genes exhibited decreased expression in *Mthfd2* KD mESCs ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Phosphorylation of H2AX (termed γ-H2AX) is one of the earliest events to occur following DNA DSB induction and is critical for protecting the genome from DSBs ([@bib49]). Interestingly, the number of γ-H2AX foci increased substantially in *Mthfd2* KD mESCs ([Figure 5](#fig5){ref-type="fig"}A) and *Mthfd2* KO mESCs ([Figure 5](#fig5){ref-type="fig"}B) with increased passaging. The increase in DNA damage in *Mthfd2* KO mESCs was further validated by comet assay, a method that measures the extent of DNA damage on a single-cell basis ([Figure 5](#fig5){ref-type="fig"}C). These increases suggested that DNA damage accumulates following *Mthfd2* depletion.Figure 5MTHFD2 Interacts with CDK1 and EXO1 to Regulate DNA Damage Level in mESCs(A and B) IF staining for γ-H2AX in *Mthfd2* KD mESCs (A) *and Mthfd2* KO mESCs (B). Representative images (left) and quantification of the average number of γ-H2AX foci per cell (right) (n = 50 nuclei) are shown. DAPI was used to indicate the nuclei. Scale bar, 10 μm.(C) DNA damage levels of *Mthfd2* KO mESCs were evaluated by the comet assay. Representative images (left) and quantification of the mean olive tail moment (right) (n = 50 nuclei) are shown. Scale bar, 100 μm.(D and E) CoIP results showing the specific interactions between endogenous MTHFD2 and both CDK1 and EXO1 in mESCs (D) and in the nuclear fraction of mESCs (E).(F and G) GST pull-down assays for interaction between EXO1-His (F), CDK1-His (G), and MTHFD2-GST fusion proteins at 250 mM NaCl containing GST binding buffer.(H) Representative results showing the EXO1 phosphorylation status in *Mthfd2* KD mESCs.Data in (A) to (C) are pooled from three independent experiments (mean ± SEM). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

MTHFD2 Interacts with CDK1 and EXO1 in the Nucleus {#sec2.9}
--------------------------------------------------

Under normal conditions, PSCs accurately repair DSBs mostly through the HR pathway ([@bib59]). EXO1 and CDK1, which play key roles in DNA HR repair ([@bib60]), were detected among the identified MTHFD2 partners ([Figure S4](#mmc1){ref-type="supplementary-material"}G and [Table S3](#mmc4){ref-type="supplementary-material"}). Thus, we explored the interactions between MTHFD2 and both EXO1 and CDK1. The interactions between endogenously expressed MTHFD2 and both CDK1 and EXO1 were confirmed by coIP experiments ([Figure 5](#fig5){ref-type="fig"}D). We further verified that MTHFD2 interacts with both EXO1 and CDK1 in the nuclear fraction ([Figures 5](#fig5){ref-type="fig"}E and S6C). Moreover, a direct interaction between MTHFD2-GST and CDK1-His was detected by GST pull-down assays ([Figures 5](#fig5){ref-type="fig"}F and 5G). These results provide evidence for the interaction of CDK1 and EXO1 with MTHFD2 in the nucleus of mESCs. In addition, the interactions between MTHFD2 and UQCRC2, CYC1, CDK1, and EXO1 remained detectable in MI-mESCs ([Figure S6](#mmc1){ref-type="supplementary-material"}D), emphasizing that the MTHFD2\'s interactions are not affected by its enzymatic activity.

During HR repair, EXO1 is primed to function in resection by CDK-mediated phosphorylation ([@bib60]). We assessed the level of CDK1-induced EXO1 phosphorylation in *Mthfd2* KD mESCs. EXO1 phosphorylation was significantly reduced in *Mthfd2* KD mESCs compared with that in control mESCs ([Figure 5](#fig5){ref-type="fig"}H). Collectively, these results indicate that *Mthfd2* plays an important role in maintaining the phosphorylation of EXO1 in mESCs.

*Mthfd2* Modulates HR Repair by Regulating EXO1 Phosphorylation {#sec2.10}
---------------------------------------------------------------

To understand whether the increased DNA damage in *Mthfd2* KD mESCs was caused by defects in DNA repair, we quantified and compared γ-H2AX foci formation after treatment with camptothecin (CPT), which induces DSBs ([@bib24]). A significant reduction in DNA repair efficiency was observed in *Mthfd2* KD mESCs ([Figures 6](#fig6){ref-type="fig"}A, 6B, [S6](#mmc1){ref-type="supplementary-material"}E, and S6F) and *Exo1* KD mESCs ([Figures 6](#fig6){ref-type="fig"}C, 6D, and [S6](#mmc1){ref-type="supplementary-material"}G) after CPT treatment, consistent with a previous report that *Exo1* deletion impairs HR repair ([@bib51]). This pattern was consistent with that observed in cells treated with RO-3306 (a specific CDK1 inhibitor), which hinders DNA repair and increases DNA damage ([Figures 6](#fig6){ref-type="fig"}E and 6F). Moreover, the comet assay results showed that forced expression of *Cdk1* effectively rescued the *Mthfd2* KD-induced impairment in DNA repair ([Figure 6](#fig6){ref-type="fig"}G). However, DNA damage level did not differ between MI-mESCs and control mESCs ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I), highlighting a key role of EXO1 phosphorylation in *Mthfd2*-mediated functions during DNA repair. Moreover, *Mthfd2* KD mESCs exhibited fewer Rad51 foci, a key component of HR repair, than control cells after CPT treatment, suggesting attenuation of HR repair ([Figures 6](#fig6){ref-type="fig"}H and 6I). These results revealed that *Mthfd2* regulates EXO1 phosphorylation by affecting the kinase activity of CDK1 to modulate HR repair and protect genomic integrity.Figure 6*Mthfd2* Modulates HR Repair by Regulating EXO1 Phosphorylation(A and B) IF staining for γ-H2AX in *Mthfd2* KD mESCs at indicated times post CPT treatment. Representative images (A) and quantification of the average number of γ-H2AX foci per cell (B) (n = 50 nuclei) are shown. DAPI was used to indicate the nuclei. Scale bar, 50 μm.(C and D) IF staining for γ-H2AX in *Exo1* KD mESCs at indicated times post CPT treatment. Representative images (C) and quantification of the average number of γ-H2AX foci per cell (D) (n = 50 nuclei) are shown. DAPI was used to indicate the nuclei. Scale bar, 50 μm.(E and F) Immunofluorescence staining for γ-H2AX in RO-3306 (RO)-treated mESCs at indicated times post CPT treatment. Representative images (E) and quantification of the average number of γ-H2AX foci per cell (F) (n = 50 nuclei) are shown. DAPI was used to indicate the nuclei. Scale bar, 50 μm.(G) DNA damage levels in OE *Cdk1*-*Mthfd2* KD mESCs were evaluated by the comet assay at indicated times post CPT treatment. Representative images (upper panels) and quantification of the mean olive tail moment (lower panel) (n = 50 nuclei) are shown. Scale bar, 100 μm.(H and I) IF staining for RAD51 in *Mthfd2* KD mESCs at indicated times post CPT treatment. Representative images (H) and quantification of the average number of Rad51 foci per cell (I) (n = 50 nuclei) are shown. DAPI was used to indicate the nuclei. Scale bar, 20 μm.All data are pooled from three independent experiments (mean ± SEM). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

*Mthfd2* Regulates Pluripotency of PSCs by Mediating Both Mitochondrial Function and HR Repair {#sec2.11}
----------------------------------------------------------------------------------------------

To further confirm whether *Mthfd2* regulates pluripotency of PSCs by mediating both mitochondrial function and HR repair, on the one hand we transfected mESCs with two sets of shRNAs against *Uqcrc2* or *Exo1*. Depletion of *Uqcrc2* or *Exo1* led to the differentiation of mESCs ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7G). Moreover, cosuppression of *Uqcrc2* and *Exo1* led to the differentiation of mESCs with reduced AP staining ([Figures 7](#fig7){ref-type="fig"}A and 7B), and the expression pattern of marker genes in these cells was more consistent with that in *Mthfd2* KD mESCs ([Figures 7](#fig7){ref-type="fig"}C and 7D). On the other hand, we forced the expression either of *Uqcrc2* or *Cdk1* alone or of *Uqcrc2* and *Cdk1* together in *Mthfd2* KD mESCs ([Figures 7](#fig7){ref-type="fig"}E and 7F). Forced co-expression of *Uqcrc2* and *Cdk1* rescued the *Mthfd2* KD-induced changes in cell morphology ([Figure 7](#fig7){ref-type="fig"}E) and marker gene expression ([Figures 7](#fig7){ref-type="fig"}G and 7H), highlighting that *Mthfd2* regulates pluripotency of PSCs by mediating both mitochondrial function and HR repair.Figure 7*Mthfd2* Regulates Pluripotency of mESCs by Modulating both Mitochondrial Function and DNA Repair(A) Representative results of *Uqcrc2-Exo1* KD mESCs with AP staining. Scale bars, 100 μm.(B) qRT-PCR analysis of mRNA levels of *Uqcrc2* and *Exo1* in *Uqcrc2-Exo1* KD mESCs.(C and D) qRT-PCR analysis of mRNA levels of pluripotency marker genes (C) and lineage marker genes (D) in *Uqcrc2-Exo1* KD mESCs.(E) Representative results of OE *Uqcrc2-*, OE *Cdk1-* or co-OE *Uqcrc2*, and *Cdk1-Mthfd2* KD mESCs with AP staining. Scale bars, 200 μm.(F) qRT-PCR analysis of mRNA levels of *Uqcrc2*, *Cdk1*, and *Mthfd2* in OE *Uqcrc2-*, OE *Cdk1-* or co-OE *Uqcrc2*, and *Cdk1-Mthfd2* KD mESCs.(G and H) qRT-PCR analysis of mRNA levels of pluripotency marker genes (G) and lineage marker genes (H) in OE *Uqcrc2-*, OE *Cdk1-* or co-OE *Uqcrc2*, and *Cdk1-Mthfd2* KD mESCs.Data in (B) to (D) and (F) to (H) are pooled from three independent experiments (mean ± SD) relative to EF1-α and the control. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (Student\'s t test) compared with the control. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

High-quality PSCs can differentiate into various types of cells more stably and efficiently, ensuring application security. Many cellular processes, such as pluripotent gene transcription, epigenetic modification, metabolic remodeling, and genomic integrity were involved in somatic cell reprogramming and cell-fate determination ([@bib12]; [@bib18]; [@bib39]; [@bib53]), but the mechanisms determining the quality of PSCs remain unclear. In our study, we performed transcriptome analysis combined with an IP-MS assay to reveal that *Mthfd2* regulates both mitochondrial function and HR repair and that *Mthfd2* is a powerful bifunctional regulator for quality of PSCs.

We found that mESCs with inhibited MTHFD2 enzymatic activity retained typical stem cell characteristics. Moreover, the expression of key genes in folate metabolism did not differ between *Mthfd2* KD mESCs and control mESCs ([Table S2](#mmc3){ref-type="supplementary-material"}). These results revealed that *Mthfd2* has non-enzymatic functions in mESCs. *MTHFD2* depletion resulted in an obvious suppression of proliferation and cell death in diverse cancer cell types ([@bib44]). In our study, homozygous *Mthfd2* KO mESCs showed compromised proliferation, but there was no significant change in cell proliferation in *Mthfd2* KD mESCs ([Table S7](#mmc1){ref-type="supplementary-material"}). Whether this difference was due to residual MTHFD2 activity in *Mthfd2* KD cells, the activity of other enzymes such as MTHFD2L, or the presence of alternative metabolic pathways that are active in mESCs, is unclear. *MTHFD2* depletion resulted in increased glycolysis in breast cancer cells and lung cancer cells ([@bib30]; [@bib45]). Our results showed that *Mthfd2* KD induces mitochondrial dysfunction, which suggests that in *Mthfd2*-depleted cells mitochondrial dysfunction may force cells to rely mainly on glycolysis to support the cellular ATP demand. However, we cannot rule out the possibility that increased glycolysis is related to mESC differentiation.

Numerous metabolic enzymes, which are often highly expressed by embryonic or undifferentiated cell types, have previously been found to have non-enzymatic functions in the nucleus ([@bib35]). In mESCs, we identified a role of nuclear *Mthfd2* in preserving HR repair. FILIA physically interacts with PARP1 and stimulates PARP1\'s enzymatic activity to regulate the DDR ([@bib68]). Our study indicated that *Mthfd2* plays a role similar to that of *Filia* in the DDR. MTHFD2 directly interacts with CDK1 and affects CDK1\'s activity to regulate EXO1 phosphorylation, thereby promoting HR repair. The most dangerous form of DNA damage is DSBs that can arise from ROS and others. *Mthfd2* overexpression in the *Drosophila* abdominal fat body significantly reduced ROS levels ([@bib64]), and ROS levels were increased in *Mthfd2* KD mESCs. Hence, *Mthfd2* can maintain genomic integrity by both reducing the levels of ROS and promoting HR repair. Genomic stability is necessary for the survival and function of PSCs ([@bib3]) and is also a key aspect of improving the quality of iPSCs ([@bib17]; [@bib27]). Therefore, *Mthfd2* improves the quality of iPSCs by maintaining genomic stability, thereby ensuring the safety of iPSC applications.

Metabolic transition from OXPHOS to glycolysis is a necessary process for successful reprogramming ([@bib15]; [@bib48]). However, OXPHOS is also induced and activated at different stages of reprogramming to jointly promote reprogramming ([@bib22]; [@bib29]). In our study, overexpression of *Mthfd2* facilitated iPSC induction, suggesting that maintaining active mitochondrial function during reprogramming is beneficial for improving reprogramming efficiency. In PSCs, the metabolic transition from glycolysis to OXPHOS promotes the primed-to-naive state transition ([@bib5]). Therefore, in addition to maintaining genomic stability, *Mthfd2* also improves the quality of PSCs by maintaining active OXPHOS. Primed PSCs have lower mitochondrial respiration rates than naive PSCs, which is attributable to a deficiency in ETC complex IV ([@bib72]). We found that deficiency in ETC complex III also affects the pluripotency state of mESCs. Complex III has two sites, Qo and Qi, to produce ROS. Antimycin A inhibits complex III at the Qi site and increases ROS generation from the Qo site, while it inhibits the Qo site and reduces ROS production ([@bib7]; [@bib9]; [@bib42]). Therefore, *Mthfd2* or *Uqcrc2* depletion may lead to increased ROS production by inhibiting the Qi site instead of the Qo site. MTHFD2 interacts with UQCRC2 to maintain active mitochondrial function, but the interaction is not direct and is mediated by other factors that need further study.

Finally, *Mthfd2* was highly expressed in high-quality iPSCs, and OSKM2 iPSCs were able to develop into viable offspring via tetraploid complementation. The tetraploid complementation assay is the most stringent criterion for assessing the developmental potential of non-human PSCs. Therefore, establishing a fast and effective method to evaluate the pluripotent state of human PSCs is necessary. Moreover, the PSCs of domestic animals such as porcine, bovine, and ovine are still unable to produce chimeras. MTHFD2 is a highly conserved protein between mice and human or domestic animals. Hence, our study should provide new insights into cell pluripotency of other species and provide additional methods to enhance and optimize the acquisition and maintenance of high-quality PSCs.

Experimental Procedures {#sec4}
=======================

Co-immunoprecipitation {#sec4.1}
----------------------

Cell extracts were prepared in lysis buffer (Beyotime) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail (Cell Signaling Technology). To reduce the background, we cleaned the cell extracts with mouse or rabbit immunoglobulin G beads before conducting coIP assays. Antibodies were incubated overnight with cell extracts and then bound to Protein-G beads (Roche) following the manufacturer\'s protocol. Beads were washed extensively in lysis buffer and then boiled in 2× SDS loading buffer before western blotting.

Data and Code Availability {#sec4.2}
--------------------------

The accession numbers for the RNA-seq data reported in this paper is SRA: SRP149554.
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